Clinical kidney trials positive
HARRY Perkins Institute of Medical Research in Nedlands recently announced a breakthrough for chronic kidney disease patients following positive clinical trials.
The treatment DMX-200 aims to control excess protein in the urine (proteinuria), a major symptom of the disease.
Without treatment, a patient’s proteinuria levels worsen, damaging the kidneys and leading to further protein leakage – creating a downward spiral of kidney function.
Results show 25 per cent of patients experienced a 50 per cent reduction in proteinuria, beyond that achieved with current standard of care therapy.
Researcher and chief scientific advisor Kevin Pfleger said it could lead to better treatment options.